Overview
Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM
Status:
Completed
Completed
Trial end date:
2017-01-01
2017-01-01
Target enrollment:
0
0
Participant gender:
Male
Male
Summary
A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizersPhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Seoul National University HospitalTreatments:
Voriconazole
Criteria
Inclusion Criteria:- Healthy male volunteer who is a CYP2C19 Poor metabolizer with rs3781727 SNP wild or
variant genotype
Exclusion Criteria:
- History of clinically significant respiratory, cardiovascular, renal, hepatic,
hematologic, neurological disorder